Sales Nexus CRM

LataMed AI to Discuss AI in Healthcare and Systems Engineering at Universidad Santa Maria

By FisherVista
LataMed AI Corp. will participate in an educational conference at Universidad Santa Maria in Caracas to discuss AI applications in healthcare and systems engineering, emphasizing professional oversight and responsible adoption.
LataMed AI to Discuss AI in Healthcare and Systems Engineering at Universidad Santa Maria

LataMed AI Corp. (OTC: LMED), a healthcare technology company focused on digital health and artificial intelligence solutions for Latin America, announced its participation in the Artificial Intelligence & Health Markets 2026 conference, scheduled for August 13 and 14, 2026, at Universidad Santa Maria in Caracas, Venezuela. The event, organized through its Venezuelan operating subsidiary LATAMEDAI VE, aims to bring together students, faculty, and professionals from systems engineering and healthcare-related fields, including pharmacy, dentistry, and laboratory sciences, to explore practical applications of AI and automation.

The company will be represented by Dr. Kevin Rodan Levy, Chief Executive Officer, and Carlos Pena, Chief Financial Officer. Their presentation is expected to address the evolving role of AI in healthcare, systems engineering, digital infrastructure, and professional decision-making. LataMed AI intends to discuss how AI-supported tools may assist healthcare professionals with medical-data evaluation, clinical workflows, and operational decision-making, as well as how automation can support the organization, reliability, and efficiency of technology systems in healthcare and other complex environments.

A key focus of the presentation will be the importance of maintaining qualified professional oversight when implementing AI. The company emphasizes that its technologies are designed to enhance human capabilities and support informed decision-making, not replace the independent judgment of healthcare professionals, engineers, laboratory personnel, or other qualified individuals. Additional conference topics are expected to include integration of AI and automation into existing systems, responsible data use, privacy and information security, operational risk management, and practical considerations in developing and deploying technology in healthcare settings.

LataMed AI also plans to discuss the continued development of its healthcare technology ecosystem, particularly the roles of CardioAI, PulmoAI, and NeuroAI within its broader strategy. These AI-supported platforms are being developed to assist healthcare professionals in evaluating and managing cardiovascular, pulmonary, and neurological health information, subject to continued development, testing, regulatory requirements, and commercial implementation.

“Artificial Intelligence & Health Markets 2026 provides an important opportunity to engage directly with students, educators, and future professionals who will help shape the responsible use of artificial intelligence in healthcare and systems engineering,” said Dr. Kevin Rodan Levy. “Our objective is to share practical perspectives on how intelligent technologies can support professional decision-making, improve digital workflows, and contribute to the continued development of healthcare infrastructure in Latin America.”

The company believes that engagement with universities can increase awareness of emerging healthcare technologies, encourage responsible discussion about AI, and strengthen relationships with future professionals. This participation aligns with LataMed AI’s broader strategy of supporting education, professional collaboration, and the responsible adoption of digital healthcare infrastructure throughout the region. The company intends to continue evaluating opportunities to participate in academic, healthcare, and technology forums that align with its business and educational objectives.

Importantly, participation in the conference does not constitute an endorsement of LataMed AI or its technologies by Universidad Santa Maria, nor does it guarantee future research collaborations, employment arrangements, commercial relationships, technology adoption, regulatory authorization, revenue, or other financial benefits. The company’s technologies remain under development and are not intended to replace the independent professional judgment of qualified providers.

For additional information, interested parties can visit LataMed AI's website or review the company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.

FisherVista

FisherVista

@fishervista